Should we continue metformin in eGFR under 30 ml/min? The visual abstract by Cristina Popa summarizes the conclusions from the Scottish cohort using target trial methodology.
KDIGO 2025 ADPKD Guidelines Review
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
Undercover Aldosterone
Undercover Aldosterone
RASi in advanced CKD - The Visual Abstract
Does initiation of ACEi and ARB help in advanced CKD? Check out the VA by Dr Nikhil John
FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Making Kidney Health a Global Priority
Heart-burn and Kidney Churn
The KDIGO CKD 2024 Guidelines Part 1: Evaluation and Risk Stratification
KDIGO CKD GUIDELINES - VISUAL ABSTRACT
Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres
🤔 Does BP lowering matter for the kidneys after all?
Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes (Ku, JASN 2023)
🤔 Coffee and the kidneys
CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction (Mahdavi, JAMA Network Open 2023)
🤔 Improving decision making in CKD
Effectiveness of an Intervention to Improve Decision Making for Older Patients With Advanced Chronic Kidney Disease (Ladin, Annals Int Med 2023)
🤔 Screening for albuminuria is cost-effective
Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis (Cusick, Annals Int Med 2023)
🤔 RASi + diuretics better than RASi + CCB in CKD?
A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality (Faucon, Kidney International 2023)
🤔 A digital intervention to increase physical activity in CKD
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK (The EMPA-KIDNEY Collaborative Group The Lancet Digital Health 2024)
🤔 EMPA KIDNEY analysis by CKD diagnosis
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
🤔 Albuminuria reduction drives Finerenone's kidney benefit
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (Agarwal et al, Annals IM 2023)
